PMID- 37535917
OWN - NLM
STAT- MEDLINE
DCOM- 20230928
LR  - 20230928
IS  - 1078-6791 (Print)
IS  - 1078-6791 (Linking)
VI  - 29
IP  - 7
DP  - 2023 Oct
TI  - Clinical Predictive Value of Phospholipase A2 Receptor Gene Polymorphism Combined 
      with Subclass of Immunoglobulin G in Renal Tissues for Membranous Nephropathy.
PG  - 418-423
LID - AT8232 [pii]
AB  - CONTEXT: Idiopathic membranous nephropathy (IMN) is a common pathologic type of 
      nephrotic syndrome, and the level of the M-type phospholipase A2 receptor (PLA2R) 
      antibody can serve as one index for predicting its progression and prognosis. 
      However, patients with the same level can show great differences in their 
      responses and prognoses. OBJECTIVES: The study aimed to explore the relationship 
      between a PLA2R gene polymorphism combined with an immunoglobulin G (IgG) 
      subclass in renal tissues and patients' responses to immunosuppressive therapy, 
      to determine the clinical prognosis for IMN patients. DESIGN: This is a 
      prospective study. Patients with new onset membranous nephropathy who need 
      treatment were selected and grouped according to the curative effect after 6 
      months of treatment. SETTING: The study took place at the First Affiliated 
      Hospital of Ningbo University, Ningbo, China. PARTICIPANTS: Participants were 60 
      patients with IMN, who had been admitted in the hospital between January 1, 2021 
      and June 30, 2022. INTERVENTION: Participants first received standard 
      immunosuppressive therapy for six months. The research team then clinically 
      divided participants into two groups: (1) a remission group with 32 participants 
      and (2) a nonremission group with 28 participants. OUTCOME MEASURES: The research 
      team: (1) compared the groups, summarizing the demographic and clinical 
      differences between the groups, (2) compared the PLA2R antibody titers at 
      baseline and postintervention between the groups, (3) analyzed the genotyping of 
      the PLA2R single nucleotide polymorphisms (SNPs) rs35771982 and rs4664308 loci as 
      well as the human leukocyte antigen (HLA)-DQA1 SNP rs2187668 locus, and (4) 
      compared the subclass IgG and PLA2R depositions in the renal tissues between the 
      groups. RESULTS: Compared with the remission group, the nonremission group 
      included significantly more males (P < .05), was significantly older (P < .05), 
      had significantly more participants with a BMI of >25 (P < .05), and included 
      significantly more participants with a positive IgG3 (P < .01) than the remission 
      group. The remission group's PLA2R antibody titers at baseline and 
      postintervention weren't significantly different from those of the nonremission 
      group. Postintervention, 24 participants in the remission group had a negative 
      conversion of PLA2R antibodies, and 22 in the nonremission group had a negative 
      conversion. The genotyping of the PLA2R SNP rs4664308 and the HLA-DQA1 SNP 
      rs2187668 loci showed no relationship to the remission rate. The GC genotype on 
      the PLA2R SNPrs35771982 locus may be a risk factor for a poor prognosis for IMN 
      patients. Moreover, the patients with a positive IgG3 in the renal tissues and 
      the GC genotype on the PLA2R SNPrs35771982 locus exhibited a poor response to 
      immunosuppressive therapy and could need intensive treatment. CONCLUSIONS: The 
      PLA2R gene polymorphism combined with the IgG subclass can predict the 
      sensitivity of IMN patients to immunosuppressive therapy.
FAU - Ji, Chunyang
AU  - Ji C
FAU - Xu, Qingqing
AU  - Xu Q
FAU - Bian, Xueyan
AU  - Bian X
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Altern Ther Health Med
JT  - Alternative therapies in health and medicine
JID - 9502013
RN  - 0 (Receptors, Phospholipase A2)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Glomerulonephritis, Membranous/drug therapy/genetics
MH  - Receptors, Phospholipase A2/genetics
MH  - Immunoglobulin G
MH  - Prospective Studies
MH  - Polymorphism, Single Nucleotide
MH  - Autoantibodies
EDAT- 2023/08/03 19:14
MHDA- 2023/09/28 06:42
CRDT- 2023/08/03 16:33
PHST- 2023/09/28 06:42 [medline]
PHST- 2023/08/03 19:14 [pubmed]
PHST- 2023/08/03 16:33 [entrez]
AID - AT8232 [pii]
PST - ppublish
SO  - Altern Ther Health Med. 2023 Oct;29(7):418-423.